Group 1: Company Overview and Strategy - Xinhua Pharmaceutical has a strong foundation in international markets due to years of experience in active pharmaceutical ingredient (API) exports, which has facilitated its transition to formulation exports [2]. - The company began its layout for formulation contract manufacturing organization (CMO) business as early as 2004, making it one of the first domestic pharmaceutical companies to do so [2]. - The strategic shift towards formulation exports is aimed at optimizing the company's industrial structure and enhancing its quality management system through international collaborations [2]. Group 2: Domestic Sales Strategy - The company is actively promoting its large formulation strategy, with a sales team of nearly 1,000 people focused on market segmentation and regional management [3]. - Xinhua Pharmaceutical has successfully participated in bidding processes, with 6 products and 8 specifications winning bids, leading to significant sales increases for products like Glimepiride and Cefradine [3]. - The company anticipates a 17% year-on-year sales growth for its self-produced raw material product, Jiening, projected to reach 10 million yuan, while Rabeprazole Sodium is expected to exceed 200 million yuan, both achieving historical highs [3]. Group 3: International Business Development - There is no conflict between domestic and international sales channels, as they operate with different teams and focus areas [3]. - The international CMO business has led to the establishment of a specialized team that emphasizes production management and quality control, enabling the company to meet international market standards [3]. - Xinhua Pharmaceutical's first ANDA product was approved in 2019, marking its entry into the U.S. market, with plans for further registrations and promotions in Europe and Belt and Road countries [3]. Group 4: Product Development and Market Trends - The company is optimistic about the market demand for its fish oil products, which are made from high-purity EPA raw materials, targeting the growing cardiovascular disease rates in China [3]. - Xinhua Pharmaceutical plans to promote fish oil through a combination of online and offline sales strategies, leveraging e-commerce and academic promotions [3]. - The upcoming "Phoenix Needle" and other aesthetic medical products represent the company's initial steps into the medical aesthetics industry, with plans for further R&D and product offerings [4]. Group 5: Pricing Strategy and Cost Management - The rise in caffeine prices is attributed to rapid increases in raw material costs due to energy consumption controls and market supply-demand dynamics [4]. - The company is enhancing upstream procurement price management and exploring new supply sources to mitigate cost increases while ensuring profit margins are maintained [4].

编号：2021-03 证券代码： 000756 证券简称：新华制药 山东新华制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | □特定对象调研 □分析师会议 | | | 动类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | √其他 | | | 参与 ...

编号：2022-01 证券代码： 000756 证券简称：新华制药 山东新华制药股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |------------|-------------------------------------------------|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | 投资者关系 | | □特定对象调研 □分析师会议 | | | 活动类别 | | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | ...

编号：2022-03 证券代码： 000756 证券简称：新华制药 山东新华制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系 | □特定对象调研 □分析师会议 | | | 活动类 ...

证券代码：000756 证券简称：新华制药 公告编号：2022-66 山东新华制药股份有限公司 关于参加山东辖区上市公司 2022 年度投资者网上集体接待日的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为增强与广大投资者的沟通互动，做好投资者关系管理工作，切实提高上市 公司透明度、规范运作和公司治理水平，山东新华制药股份有限公司（以下简称 "公司"）将参加由山东证监局、山东上市公司协会联合举办的"2022 年山东 辖区上市公司投资者网上集体接待日"活动，本次活动由深圳市全景网络有限公 司承办，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的路演平台进行 线上交流，投资者可以登录全景网"投资者关系互动平台"（http://ir.p5w.net/） 参与公司本次投资者集体接待日活动，活动时间为 2022 年 11 月 16 日（周三） 14:00 至 16:00。 届时公司董事长贺同庆先生、董事/总经理徐文辉先生、董事/财务负责人侯 宁先生及董事会秘书曹长求先生将通过网络在线交流的形式，与投资者就公司治 理及社会责任/ESG、 ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 1,789,023,665.87, representing a 28.79% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was CNY 99,053,729.45, an increase of 16.19% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 95,189,524.32, up 44.11% from the previous year, driven by expanded sales opportunities[8]. - The basic earnings per share for Q3 2022 was CNY 0.15, a 7.14% increase year-on-year[5]. - The diluted earnings per share remained stable at CNY 0.14, with no change compared to the previous year[5]. - The company reported a net profit margin improvement, with net profit increasing alongside revenue growth, although specific figures were not disclosed in the provided content[24]. - The net profit for the current period is 303,195,955.06, an increase from 297,252,235.38 in the previous period, representing a growth of approximately 1.3%[27]. - The total profit for the current period is 334,607,994.44, compared to 340,012,441.58 in the previous period, showing a decrease of about 1.2%[27]. - The operating profit for the current period is 338,081,275.06, slightly down from 344,208,270.78 in the previous period, indicating a decline of around 1.8%[27]. - The total comprehensive income for the current period is 281,032,140.69, compared to 249,238,018.45 in the previous period, indicating an increase of about 12.8%[27]. Assets and Liabilities - The total assets at the end of Q3 2022 reached CNY 8,194,604,106.80, a growth of 11.76% compared to the end of the previous year[5]. - Total assets reached ¥8,194,604,106.80, compared to ¥7,332,033,657.98 at the beginning of the year, indicating a growth of 11.8%[20]. - Total liabilities increased to ¥4,001,250,874.08 from ¥3,680,888,823.85, marking a rise of 8.7%[23]. - The company's equity attributable to shareholders rose to ¥3,972,802,737.29 from ¥3,467,941,567.45, an increase of 14.6%[23]. - Cash and cash equivalents increased to ¥1,212,766,900.26 from ¥744,662,302.34, representing a growth of 62.8%[19]. - Cash flow from operating activities for the current period is 233,819,696.10, compared to 230,422,146.43 in the previous period, reflecting a marginal increase of about 1.3%[30]. - The cash and cash equivalents at the end of the period amount to 1,049,450,512.26, an increase from 675,142,439.65 in the previous period, representing a growth of approximately 55.4%[33]. Costs and Expenses - Total operating costs amounted to ¥5,118,017,176.96, up 11.4% from ¥4,594,778,972.14 year-on-year[24]. - Research and development expenses were ¥258,495,146.14, reflecting an increase from ¥247,397,181.53 in the previous year[24]. - The company received government subsidies amounting to CNY 6,084,676.54 during the reporting period[7]. Cash Flow - The company reported a net cash flow from operating activities of CNY 233,819,696.10, which is a 1.47% increase year-to-date[5]. - Cash flow from financing activities shows a net increase of 376,795,259.04, a significant improvement from a net outflow of -100,041,207.71 in the previous period[33]. - The company received cash from investment activities amounting to 16,115,180.00, up from 9,993,236.39 in the previous period, marking an increase of approximately 61.5%[30]. Inventory and Borrowings - Inventory decreased to ¥970,173,470.97 from ¥1,027,539,968.72, a decline of 5.6%[19]. - Short-term borrowings increased to ¥382,448,776.17 from ¥269,455,217.71, reflecting a rise of 42.0%[20]. Return on Equity - The weighted average return on equity was 2.52%, a slight decrease of 0.01 percentage points compared to the previous year[5].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 3.66 billion, representing a 3.19% increase compared to CNY 3.55 billion in the same period last year[14]. - Total profit decreased by 9.62% to approximately CNY 235.32 million from CNY 260.36 million year-on-year[14]. - Net profit attributable to shareholders of the listed company was approximately CNY 194.39 million, a decrease of 2.85% compared to CNY 200.08 million in the previous year[14]. - The basic earnings per share decreased by 6.25% to CNY 0.30 from CNY 0.32 in the same period last year[14]. - The weighted average return on net assets decreased by 0.77 percentage points to 5.23% from 6.00% year-on-year[14]. - The gross profit margin decreased by 3.29 percentage points to 26.00% from the previous year[61]. - The company reported a total operating cost of RMB 3,423,882,303.99 for the first half of 2022, compared to RMB 3,266,899,130.92 in the same period of 2021, marking an increase of about 4.8%[142]. - Operating profit for the first half of 2022 was RMB 237,764,708.38, compared to RMB 263,189,820.50 in the first half of 2021, indicating a decrease of about 9.7%[142]. Cash Flow and Financial Position - The net cash flow from operating activities increased by 17.99% to approximately CNY 194.80 million from CNY 165.10 million year-on-year[14]. - Cash and cash equivalents increased by 49.16% to RMB 1,110,709,989.56 compared to the previous year[52]. - The company reported a significant increase in cash and cash equivalents, with a net increase of RMB 361,491,631.08, a rise of 268.31% compared to RMB 98,149,083.00 last year[58]. - The total debt of the company as of June 30, 2022, was RMB 1,669,497,000, with cash and cash equivalents amounting to RMB 1,110,710,000[64]. - The company's asset-liability ratio stood at 48.76%[67]. - The total liabilities reached RMB 3,874,926,203.14, up from RMB 3,680,888,823.85, indicating an increase of 5.3%[134]. - Cash flow from operating activities generated a net amount of RMB 194,801,492.76, up from RMB 165,101,447.08 in the previous period, reflecting an increase of approximately 18.05%[147]. Shareholder Information - The company plans not to distribute cash dividends or bonus shares for this reporting period[8]. - The total number of shares increased to 669,627,235, with 94.281% being unrestricted shares[18]. - The top shareholder, Hualu Holdings Group Co., Ltd., holds 204,864,092 shares, accounting for 30.59% of the total shares[20]. - The company reported a total of 3,000 shareholders as of June 30, 2022[18]. - The company’s board of directors has proposed not to distribute a dividend for the first half of 2022, compared to zero dividends in the first half of 2021[74]. Research and Development - The company has established a comprehensive research and development system with over 100 products in the pipeline, focusing on new drug development and innovative technologies[72]. - The company has initiated the construction of the first phase of the Gene and Cell Engineering Center[37]. - The company obtained 5 new product approvals and 2 consistency evaluation approvals in the first half of 2022[37]. - Research and development expenses were RMB 164,668,702.95, showing a slight increase of 0.51% from RMB 163,835,401.81 in the previous year[57]. Market and Sales Performance - The company exported products worth USD 181 million, reflecting a year-on-year growth of 3.63%[36]. - Sales of the top 10 strategic formulations increased by 14% year-on-year[36]. - The international formulation processing and export sales grew by 17.31% year-on-year[36]. - Sales of pharmaceutical intermediates from Xinhua Shouguang Company increased by 31.3% year-on-year[36]. - The company’s health technology division achieved a sales growth of 15.56% year-on-year despite pandemic challenges[36]. Environmental Compliance and Initiatives - The company is committed to complying with environmental regulations and is increasing investments in environmental protection facilities to mitigate risks associated with production waste[77]. - The company has reported no administrative penalties related to environmental issues during the reporting period[80]. - The company has established strict emission standards for wastewater and waste gas, ensuring compliance with national regulations[81]. - The company has implemented a dual-pipe technology to eliminate odors during the handling and transportation of chemical raw materials and products[91]. - The company has established three wastewater treatment facilities with a total processing capacity of 12,000 tons per day, ensuring compliance with wastewater discharge standards[86]. Corporate Governance - The company has established an audit committee in compliance with listing rules, ensuring adherence to accounting principles and internal controls[127]. - The company confirmed compliance with corporate governance codes, with no deviations reported during the six months ending June 30, 2022[126]. - The company has appointed three independent non-executive directors, ensuring at least one possesses appropriate financial management expertise[128]. Financial Instruments and Accounting Policies - The company classifies financial assets based on the business model and cash flow characteristics, including those measured at amortized cost and those measured at fair value with changes recognized in other comprehensive income[188]. - Financial liabilities are classified at initial recognition as either measured at fair value with changes recognized in profit or loss, or as other financial liabilities[197]. - The fair value of financial assets and liabilities is determined using market prices or valuation techniques, prioritizing observable inputs[199].

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion, representing a growth of 15% compared to the previous year[15]. - The net profit for the year was RMB 300 million, reflecting a 10% increase year-over-year[15]. - Operating income for 2021 reached RMB 6,560,077,586.40, representing a 9.23% increase compared to 2020[19]. - Net profits attributable to shareholders of the listed company increased by 7.29% to RMB 348,548,495.99 in 2021[19]. - The net profit attributable to the company for 2021 was RMB 57,212,663.89, an increase from RMB 34,069,550.32 in 2020, representing a growth of about 68%[27]. - The company has set a performance guidance for the next year, aiming for a revenue target of RMB 1.8 billion, which would represent a 20% increase[15]. - The gross profit margin improved to 40%, up from 35% in the previous year, indicating better cost management and pricing strategies[79]. Customer Growth - User data showed an increase in active customers, reaching 2 million, which is a 20% growth from the previous year[15]. - User data indicates a growing customer base, with an increase of 25% in active users compared to the previous year, reaching 500,000 active users[79]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[15]. - The company plans to expand its market presence in Southeast Asia, with an investment of 50 million RMB allocated for marketing and distribution channels[79]. Product Development - New product development includes the launch of three innovative pharmaceutical products, expected to contribute an additional RMB 200 million in revenue[15]. - New product development is underway, with three new pharmaceutical products expected to launch in Q3 2022, targeting a market share increase of 10%[79]. Strategic Initiatives - A strategic acquisition of a smaller pharmaceutical firm was completed, enhancing the company's product portfolio and expected to generate an additional RMB 150 million in annual revenue[15]. - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's production capacity by 30%[79]. Research and Development - The company has allocated RMB 100 million for research and development in new technologies for the upcoming fiscal year[15]. - The company is investing in advanced technology for drug development, with a budget of 100 million RMB dedicated to R&D over the next two years[79]. Sustainability and Corporate Responsibility - The board emphasized the importance of sustainability and corporate social responsibility initiatives, with a budget of RMB 50 million allocated for environmental projects[15]. - The company has initiated a new sustainability strategy aimed at reducing carbon emissions by 25% by 2025[79]. Financial Position - The company reported a strong cash flow position with RMB 500 million in cash reserves, providing a solid foundation for future investments[15]. - Total assets as of December 31, 2021, were RMB 7,332,033,657.98, reflecting a 3.37% increase from the previous year[19]. - Total liabilities decreased by 0.56% to RMB 3,680,888,823.85 as of December 31, 2021[19]. Shareholder Information - The total number of shares as of December 31, 2021, was 627,367,447, an increase from 621,859,447 shares in 2020[36]. - The company plans to propose a final dividend of RMB 0.15 per share based on a total share count of 669,627,235, subject to shareholder approval[62]. - The proposed A share issuance is currently in progress, and the Company will not discuss the profit distribution plan for 2021 until after the issuance is completed[61]. Management and Governance - The term of the current Directors, Supervisors, and Senior Officers will end on December 22, 2023[101]. - The company operates independently from its controlling shareholder in terms of business, assets, management, and finance[156]. - The Company has established clear responsibilities among its governance structures, including the board of directors and supervisory committee[162]. Internal Controls and Auditing - The Audit Committee confirmed that the financial statements for 2021 were prepared in accordance with the Company's accounting policies and were accurate without any material misrepresentations[143]. - An independent audit on the effectiveness of the Company's internal control was conducted by ShineWing, ensuring transparency and accountability[174]. - The internal control audit report confirmed that the Company maintained effective internal control over financial reporting as of December 31, 2021, in compliance with relevant regulations[183][186].